Algorithms designed to precisely identify disease severity for a given patient within a managed care population are helpful in organizing targeted interventions. These algorithms are also attracting considerable attention within the medical research community. Several health risk screening instruments have been developed; however, these involve survey methodologies and have several shortcomings. We present a valid and efficient method for predicting healthcare resource utilization among asthmatics in an Health Maintenance Organization (HMO) population. First, various diagnosis, procedure and pharmacy billing codes were used to identify the asthmatics within the database. The screening algorithm awards points each time one of these codes is identified for an HMO member. By varying the number of points necessary to consider a patient asthmatic, the sensitivity, specificity, positive and negative predictive values of the algorithm can be adjusted. Once identified as asthmatic, subjects were then stratified into severity levels based on pharmacy data. Severity stratification was validated directly by measuring asthma-related bed days utilized during the 12 months following the date of stratification. Our identification algorithm estimated an asthma prevalence of 3.84% within the studied population, with age-specific prevalence estimates that closely mirrored previously published survey data. There was a monotonic relationship between pharmacy severity levels and inpatient resource utilization. For example, asthmatics in severity level 1 used only 92 hospital days per 1000 asthmatics in the year following characterization, while those in levels 2-5 used 133, 156,277 and 1168 hospital days (P<O.OOl), respectively. Results from this model can be used as adjusters in other predictive models or stand alone to represent a patient's severity of illness.
Introduction and purpose
As insurers continue to develop sophisticated disease management programs, their ability to identify and characterize patients with selected chronic diseases is attracting more attention within the medical research community. Identifying patients with a specific chronic disease is necessary to determine who is at risk for avoidable and often costly exacerbations. Further characterizing those with a disease helps to precisely identify the level of severity for a specific patient so that targeted interventions, consistent with an individual's needs, can be provided. Together, identification and characterization of the population enables healthcare providers to efficiently expend healthcare education and other resources on those who may need them the most.
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$12.00/O administered to insureds or providers via the mail or the telephone. However, these survey methodologies have several shortcomings. First, they are typically very expensive due to mail, telephone and personnel costs. Additionally, such methodologies often yield invalid and incomplete information. For example, response rates for traditional mail surveys under these circumstances are typically less than 20% (1) . Furthermore, the validity of the information gained from those who do respond is suspect consequent to substantial respondent recall errors or intentional misrepresentation. Administrative claims and encounter data can be used to solve many of the efficiency and validity shortfalls associated with survey data. Administrative claims and encounter data are already available to insurers for billing and other purposes. Therefore, the costs associated with survey administration are avoided. Furthermore, such data sources are generally accurate representations of services provided to and received by individual insureds. Finally, these data are not dependent upon response rates or respondent recall.
The purpose of this article is to present an improved valid and efficient methodology designed to identify and characterize patients with asthma within an HMO population.
We selected this disease since it is prevalent, chronic and potentially costly when inappropriately managed, and its course can be affected with appropriate disease management. The general methodology presented here can be applied to other chronic diseases as well.
Methods

DATA
Data for this study were obtained from a large HMO with more than 2 million fully-insured members and operating in 13 eastern states plus the District of Columbia. Specific data sources included pharmacy claims, specialist claims, inpatient claims, radiology claims, laboratory claims, primary care provider encounter information and administrative membership information.
Each data source was linked to a patient-specific identification number to create one omnibus data source.
All HMO members who met specific criteria suggesting the presence of asthma were eligible for the study. The sample used for the study was narrowed to include only those who were members for a minimum of 12 months starting in October 1994 and who had a pharmacy plan. These criteria ensured that individual members had enough history with the HMO to generate claims and encounter data, if appropriate.
The resultant sample consisted of 28 6 16 insured members. Table 1 presents the diagnosis, procedure and pharmacy billing codes that were used to identify asthmatics. Each code was widely accepted as asthma-specific or related. Programs were created to identify those who had any of the codes. Each time one of the codes represented in Table 1 came up for an HMO member, the individual was awarded a point. With this methodology, the specificity, sensitivity, negative and positive predictive values of the screening algorithm could be adjusted contingent upon the number of points required to consider an individual an asthmatic (2) . Since many of these codes could be present for nonasthmatics, specific selection criteria were incorporated. These criteria were decided upon as a result of a feedback process where the HMO would field lists of asthmatics to the primary care physician population.
MEASUREMENT
In turn, the primary care physicians would return information indicating which patients were falsely labeled as asthmatic and which were incorrectly left off the list. The results were then evaluated to identify what could be done to improve the identification codes and algorithms.
In this way, the misclassification errors previously reported (3) could be minimized. While this method of algorithm validation suffers from physician non-response to the survey, we have no reason to believe that the responses were biased in any way. These surveys were used to guide the research team to those observations that warranted closer scrutiny to determine the potential cause for misclassification.
Of course, those who were misidentified would probably be in the lowest severity "Aetna U.S. Healthcare internal codes **sufficient if met on more that one claim at least 30 days apart in the age group O-44 years and no diagnosis criteria for chronic obstructive pulmonary disease category resulting in no impact on the application of the severity adjustment addressed here.
The following selection criteria were used to increase the positive predictive value of our identification logic. First, an individual had to have at least three points from any database or have two points represented in at least two databases (i.e. pharmacy, laboratory, claims and/or encounters) to be considered asthmatic. Since we were seeking to identify patients with chronic asthma, more than a single episode of wheezing was required. Additionally, if a patient was awarded all of his or her points from the pharmacy data, these points had to occur within a 12-month period. These requirements limited the number of false positives yielded from pharmacy data, given that some of the medications used for asthma may be used for other ailments. Finally, the evaluation of theophylline levels and the medications listed in Table 1 are used for chronic obstructive pulmonary disease (COPD) as well as for asthma. To further increase the positive predictive value of the identification algorithm and to avoid falsely concluding that an individual with COPD had asthma, all points derived from pharmacy and laboratory databases were voided for individuals who were older than 44 years of age or diagnosed with COPD.
STRATIFICATION
Patients who were identified as asthmatic were then stratified into pharmaceutically driven severity groups. Clinical definitions of severity, based on medication class requirements, have been previously published (4,5) but fail to account for differences in the amount of medication used. The concept of mild, moderate and severe asthma was further developed into five ordinal pharmacy severity levels. The specific pharmaceutical criteria were determined based on a series of focus group interactions and collaboration with the National Heart, Lung and Blood Institute's Asthma Clinical Research Network, and researchers from the HMO. Individuals in the first two severity levels are considered mild asthmatics since they were dispensed /?-agonists alone. Since their asthma is being controlled only with P-agonists, these individuals are not likely to have significant disease. However, given the nature of the current clinical guidelines (4, 5) , asthmatics who require P-agonist inhalations more than once daily should be considered poorly controlled and should be placed on inhaled corticosteroids (ICS). Therefore, the mild asthmatics were separated into two groups to investigate whether or not those who required three or fewer j-agonist prescriptions per year would utilize fewer hospital resources than those requiring four or more.
Those who required other asthma medications, such as xanthines, chromolyn, or anti-cholinergics but not inhaled steroids (ICS) were classified in the third severity category. In this group, the risk of an exacerbation is probably higher because the use of ICS is generally reserved for patients who experience persistent symptoms despite p-agonists. In addition, none of the other medications (except ICS) are generally considered as useful in relieving symptoms or aborting exacerbation as the P-agonists, so their presence may imply a higher risk for resource utilization. Of course, this group also includes the occasional patient who cannot tolerate b-agonists, or who may have technical difficulty with inhaler use. Regardless of the reason for their inclusion, the presence of other asthma medications is likely to signal more serious disease.
Initiation of oral steroids defines a severely ill asthmatic (4, 5) . Asthmatics who were dispensed oral steroids were placed in the highest severity levels. By similar logic, this group was further broken into two groups. The fourth level included those who were dispensed fewer overall asthmaspecific medications when compared to those in the fifth severity level. Using the amount of systemic steroid therapy, in combination with the amount of P-agonist dispensed, to define the most severe categories was done in order to minimize confounding by the multiple other conditions treated with steroids.
VALIDATION
Validation of the asthmatic identification model algorithm was accomplished primarily through the use of prevalence rate comparisons with other research. Here the prevalence rates were stratified by age to allow for comparisons with 1987 National Health Interview data (6) and research conducted by Dodge and Burrows (7). These works were chosen as references because of their widespread clinical acceptance. The census data is generally accepted as reflective of the overall prevalence rates in the U.S.A. population, and the Dodge and Burrows data are believed to accurately represent age stratified prevalence rates.
Severity characterization was validated directly by measuring the asthma-related bed days per thousand for each severity level, during the 12 months following the period when asthmatics were assigned severity levels. Our u priori expectations are that those in higher severity categories will use more bed days per thousand than those in lower severity categories if the pharmaceutically driven severity levels are accurate characterizations of the asthmatic populations' risk of exacerbation. We selected asthma-related bed days per thousand consequent to the increased accuracy of inpatient diagnosis data provided in the HMOs claims system. Only those admissions containing asthma-related primary diagnoses were included in the bed day counts.
Results
The overall prevalence of asthma in the study population was estimated to be 3.84%. This result correlated well with the results from the 1987 National Health Interview statistics suggesting an overall 4% asthma prevalence rate. Age stratified comparisons also suggest very close agreement between the National Health Insurance Survey (NHIS) prevalence rates (i.e. 0.053 for those below 18 years, 0,035 for those 18 to 44 years and 0.038 for those greater than 44 years) and those of this methodology (i.e. 0.066, 0.031 and 0.01, respectively). Compared with the Dodge and Burrows' data, the age-specific prevalence rates show more variation (see Fig. 1 ). The HMO data suggests a noticeably higher prevalence rate in the lowest age group. The lower prevalence rate presented in the HMO data for older age groups is likely to be a function of the positive predictive value enhancing criteria introduced to avoid misclassification with COPD. Figure 2 displays the percentage of asthmatics who fell within each of the five severity levels. Forty-nine percent of the asthmatics are in the lowest two severity levels, requiring only P-agonists for control. Twentji-four percent of the population fell into pharmacy severity level 3 and 27% were in severity levels four and five combined.
Our expectations were that those in the highest severity levels would be the most likely to have an acute exacerbation necessitating hospital admission. As expected, there was a monotonic relationship between patient severity level and the number of asthma-related bed days per thousand (Fig. 3) . Only 92 hospital days per 1000 patients per year were utilized by those asthmatics in level 1. Level 2 asthmatics required 133 days per 1000 patients annually. asthmatics, level 4 patients required 277 days, and level 5 patients utilized 1168 hospital bed days per 1000 patients per year. To test if there was a statistically significant difference in the number of asthma-specific inpatient days among the different severity levels, several statistics were calculated. First, an analysis of variance was calculated yielding an overall P-value of less than 0.001, therefore, rejecting the null hypothesis that the mean hospital days of the different severity level groups are equal (see Table 2 ). Second, four a priori hypotheses were tested to determine which, if any, of the severity levels yielded a significantly different average number of asthma-specific bed days when compared to its adjacent severity levels. Hence, the average days per thousand for severity level 1 was compared with severity level 2, severity level 2 was compared with severity level 3, level 3 was compared with 4, and 4 was compared with 5. The results of these comparisons were mixed (see Table 3 ). Severity level 1 was not significantly different from 2 and severity level 2 was not significantly different from 3. However, severity level 3 was significantly different from 4 (P<O.OOl), and Our study is somewhat limited by the relative inability to accurately estimate the identification algorithm's specificity and sensitivity to the identification measure. Consequent to the limited nature of claims data, we could only conduct an indirect validation by comparing our administrative data derived prevalence rates with those of previous research. We believe that the general logic behind the identification algorithm is sound, and that its greatest utility is in identifying severely ill asthmatics at highest risk of significant morbidity.
Based on the comparisons with other published asthma prevalence rates, our estimates appear to yield higher estimates in the younger population and lower estimates in the older population.
The relatively high results could be the result of the inclusion of selected medications that are used for conditions other than asthma in the pediatric population.
We expect that most of our false positives were in severity strata one and two. Our lower estimates are probably the result of our exclusion criteria for those over the age of 44 and those who had a diagnosis of COPD. Without additional primary data collection, it is not possible to determine whether or not previous studies yielded over-estimates or whether our estimates are too low. The results from this severity stratification can be used as inputs into more thorough models that take other risk factors into account. Age, gender and socio-economic status have been linked to the severity of several chronic diseases. Additional research is needed to identify these factors' joint ability to identify high-risk individuals.
Because sufficient information must be available for extended periods in order to identify and stratify individual patients, this methodology may only be appropriate for those with chronic diseases. Since acute illnesses have a rapid onset, such administratively driven identification and stratification methodologies may yield less useful results. As information systems become more sophisticated and data are collected in a more timely manner, acute care severity stratification can be developed such that clinicians could obtain severity information about their practice populations in real time. Application of this severity stratification methodology to other diseases could be used as predictors in other statistical adjustment models or stand alone to represent a patient's severity of illness.
Additional research must be conducted to help refine interventions that have an impact on resource utilization and the health status of those in higher severity groups. Since those in higher severity groups are already receiving medications designed for high-risk patients, new nonpharmaceutical interventions must continue to be further explored and tested to determine their impact. Indeed, it is likely that primary care physicians have already identified many high-risk patients. As such, payers, employers and managed care companies must determine the best ways to help providers better care for this population. More research is necessary to determine what mix of patient education, patient counseling, disease management, home health care, primary care physician education, specialist care and other services would yield optimal health results for specific populations. 
